Excretion and Common Side Effects of Fluorouracil 5% and Calcipotriene 0.005%
Fluorouracil 5% Excretion
Fluorouracil is primarily eliminated through rapid hepatic catabolism, with 60-90% of the administered dose excreted in urine within 24 hours, mainly as the metabolite alpha-fluoro-beta-alanine 1. When applied topically, systemic absorption is minimal 2.
The elimination pathway follows this sequence:
- Rapid hepatic catabolism is the primary route of elimination 3
- Plasma half-life: approximately 8-20 minutes after parenteral administration 3
- Urinary excretion: 60-90% within 24 hours, predominantly as metabolites 1
- Biliary excretion: accounts for only 2-3% of total elimination 1
The drug undergoes sequential metabolism: fluorouracil → dihydrofluorouracil (half-life ~62 minutes) → alpha-fluoro-beta-ureidopropionic acid (half-life ~239 minutes) → alpha-fluoro-beta-alanine (half-life ~1976 minutes), which is the primary urinary metabolite 1.
Calcipotriene 0.005% Excretion
The provided evidence does not contain specific excretion data for calcipotriene. However, as a vitamin D analogue used topically, systemic absorption is minimal when used as directed 4.
Most Common Side Effects
Fluorouracil 5% Side Effects
The most frequent adverse reactions are localized skin reactions directly related to the drug's pharmacological activity 2:
Primary local reactions include:
- Burning
- Crusting
- Pruritus (itching)
- Erythema (redness)
- Ulceration
- Scarring
- Rash
- Soreness
- Allergic contact dermatitis 2
Less common but notable reactions:
- Leukocytosis (most frequent hematological effect) 2
- Emotional upset, insomnia, irritability 2
- Alopecia, blistering, scaling 2
- Conjunctival and corneal reactions if applied near eyes 2
Critical safety warning: Fluorouracil applied to mucous membranes has caused ulcerations, miscarriages, and birth defects (ventricular septal defect) 2. The drug should never be applied to eyelids, eyes, nose, or mouth 2.
Calcipotriene 0.005% Side Effects
Common local reactions include:
- Burning
- Itching
- Skin irritation 5
- Pruritus (65% of patients initially, decreasing to 10% at treatment end) 4
Important consideration: When combined with betamethasone in pediatric patients, one case of transient mild HPA (hypothalamic-pituitary-adrenal) suppression occurred, which resolved after discontinuation 4.
Combination Therapy Advantages
The combination of fluorouracil 5% with calcipotriene 0.005% demonstrates reduced local site reactions compared to fluorouracil monotherapy 5. Clinical trials show that this combination effectively treats actinic keratosis with minimal adverse effects impacting treatment success, while reducing the lengthy treatment duration associated with existing therapies 5, 6.
Key safety consideration: Calcipotriene should be used cautiously in patients with calcium metabolism disorders or renal disease 4.